Back to search results
NCT06792175

Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models

Enrolling by Invitation
Not specifiedAges 13–60Observational
Psyrin Inc.
~500 participants
Updated 2025-09-03 on ClinicalTrials.gov
What's tested:Solicue Machine Learning ModelsMercuria Machine Learning Models

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Speech Battery ("PSY-10") audio
Measured over At initial assessment
+2 more outcomes measured

Conditions

Autism Spectrum Disorder
Depression - Major Depressive Disorder
Anxiety, Generalized
Bipolar Disorder (BD)
Attention Deficit Hyperactivity Disorder (ADHD)
Schizophrenia Spectrum &Amp; Other Psychotic Disorders
Post Traumatic Stress Disorder
Obsessive Compulsive Disorder (OCD)

Explore related trials

Attention Deficit Hyperactivity DisorderAutism Spectrum DisorderBipolar DisorderGeneralized Anxiety DisorderMental HealthObsessive Compulsive DisorderPost-Traumatic Stress DisorderSchizophrenia Spectrum and Other Psychotic DisordersUnipolar Depression

Where it's being run

2 sites across 2 states
Massachusetts1
Ohio1

Study leadership

  • Julianna Olah, B.Sc., M.A., M.Sc., Ph.D. · PRINCIPAL_INVESTIGATOR · Psyrin Inc.
  • Atta-ul Raheem R Chaudhry, B.Sc. (Hons.), M.B.B.S. · PRINCIPAL_INVESTIGATOR · Psyrin Inc.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Speech Battery ("PSY-10") audioAt initial assessment

    The speech battery consists of prompt-based tasks designed to elicit speech responses from participants in the form of monologues. This includes text reading, recall, and picture description tasks.

  • Clinical diagnosis0 months, 3 months, 6 months

    Clinician diagnosis will be recorded for each participant at first assessment, 3-month, and 6-month follow-up. Diagnoses will be made according to ICD-11 or DSM-5 criteria for the compatible disorders: ADHD, ASD, BPAD, GAD, MDD, OCD, PTSD, and SSD. Additional relevant labels such as other mental health disorders, clinical high risk (CHR) and substance use may be recorded.

  • Performance of AI models0 months, 3 months, 6 months

    The performance of the Mercuria and Solicue AI models will be evaluated using performance metrics of accuracy, balanced accuracy, sensitivity (recall), specificity, positive predictive value (precision), negative predictive value, F1 score, AUC-ROC. Predicted labels will be compared with the ground truth clinical diagnoses obtained from the participating mental health clinics. Confidence acceptance threshold will be set.